Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marcus Jamil

Urology Plymouth, MI Medical Doctor

NPI 1063948982 CMS profile 4227825

14300 N Beck Rd, Plymouth, MI 48170

Open in the dashboard

General payments

$102,755

30 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marcus Jamil of Plymouth, MI is reported in the CMS Open Payments database as having received $102,755 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $187 6
2024 General $199 2
2023 General $51,984 11
2022 General $50,083 5
2021 General $154 3
2020 General $59 2
2019 General $89 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marcus Jamil
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Marcus Jamil were reported at $187. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Marcus Jamil Urology median Middle half National median
2019 $89 $480 $147–$1,201 $163
2020 $59 $246 $87–$645 $114
2021 $154 $358 $111–$1,000 $132
2022 $50,083 $476 $143–$1,263 $149
2023 $51,984 $560 $168–$1,461 $160
2024 $199 $563 $170–$1,464 $164
2025 $187 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $102,404 21 payments
  2. Coloplast Corp $116 3 payments
  3. Laborie Medical Technologies Corp. $112 1 payment
  4. CONMED Corporation $45 1 payment
  5. Endo USA, Inc. $44 2 payments
  6. Myovant Sciences Inc. $21 1 payment
  7. Tolmar, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $100,000 2 payments
  2. Travel and Lodging $1,243 5 payments
  3. Food and Beverage $1,232 22 payments
  4. Education $280 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL - ERECTILE DYSFUNCTION Erectile Dysfunction $50,000 1 payment
  2. AMS 700 CXR RTE Kit $1,644 7 payments
  3. GENERAL MALE SUI $113 1 payment
  4. Optilume BPH Drug Coated Balloon Catheter $112 1 payment
  5. AMS 700 $109 2 payments
  6. AMS $104 2 payments
  7. Titan $101 2 payments
  8. General - Erectile Dysfunction General - Erectile Dysfunction_URO $52 2 payments
  9. XIAFLEX $44 2 payments
  10. AMS 800 Artificial Urinary Sphincter $22 1 payment
  11. Other $83 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

358

Median for Urology: 1,053

Drug cost

$76,434

Median for Urology: $101,464

Branded share of claims

26.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 47 $54,629
Mirabegron Er Mirabegron Brand 20 $15,771
Trospium Chloride Generic 38 $2,704
Tamsulosin Hcl Generic 119 $2,125
Estradiol Generic 11 $494
Finasteride Generic 18 $377
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 16 $114
Ciprofloxacin Hcl Generic 42 $105
Cephalexin Generic 34 $101
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$50,769

Medicare's payments for the services billed

Medicare patients

216

Average age 74

Services billed

745

46 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 44%
Arthritis 44%
Chronic kidney disease 42%
Diabetes 40%
Cancer 31%
Depression 28%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record